COMMUNIQUÉS West-GlobeNewswire

New “Test and Treatment” Allergy Program Enables All Physicians To Provide Convenient And Effective Allergy Care

19/12/2017 - 14:17

New York City, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Pediatric Allergy Solutions (“PAS”) and Allovate Therapeutics (“Allovate ® ”) announce that they have signed an exclusive agreement to combine PAS’s simple and minimally [...]

Minerva Neurosciences Screens First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in Schizophrenia

19/12/2017 - 14:00

Multi-center, international trial targets significant unmet need for which no treatments are approved Approximately 500 patients to be enrolled at 60 clinical sites in U.S. and Europe WALTHAM, Mass., Dec. 19, 2017 ( [...]

Opiant Pharmaceuticals to Ring The Nasdaq Opening Bell on December 20, 2017

19/12/2017 - 14:00

SANTA MONICA, Calif., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT ), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced [...]

Tyme to Present Efficacy Data on SM-88 in Pancreatic Cancer at 2018 ASCO Gastrointestinal Cancers Symposium

19/12/2017 - 14:00

NEW YORK, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (Nasdaq: TYME ), a clinical-stage biotechnology company developing cancer therapeutics, today announced that efficacy data from its lead therapy SM-88 [...]

VBI Vaccines Announces Initiation of Phase 3 Clinical Program for Sci-B-Vac® Hepatitis B Vaccine

19/12/2017 - 14:00

Patient dosing commenced on December 18, 2017 4,800 subjects across two Phase 3 studies: PROTECT and CONSTANT 15-month program - headline data expected Q2 2019 CAMBRIDGE, Mass., Dec. 19, 2017 (GLOBE NEWSWIRE) -- VBI [...]

Ovid Therapeutics Announces OV101 Granted Fast Track Designation by U.S. FDA for Treatment of Angelman Syndrome

19/12/2017 - 14:00

NEW YORK, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID ), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today [...]

Apixio’s AI-Based Technology Delivers More Accurate Risk Adjustment to Meet Industry Demand for Compliant Solutions

19/12/2017 - 14:00

SAN MATEO, Calif., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Apixio Inc., the data science company for healthcare , is enabling healthcare organizations across the country to gather a more accurate picture of actively treated [...]

INSYS Therapeutics Initiates Phase 2 Clinical Trial of Cannabidiol (CBD) Oral Solution for Treatment of Refractory Childhood Absence Epilepsy in Pediatric Patients

19/12/2017 - 14:00

PHOENIX, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Can a synthetic formulation of cannabidiol (CBD), one of the main molecules in cannabis, safely help control treatment-resistant “staring” seizures in children with epilepsy? [...]

Delcath Announces Preliminary Safety Analysis for Phase 3 Focus Trial

19/12/2017 - 14:00

NEW YORK, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the independent Data [...]

Xbrane Biopharma signs agreement with BL&H for sales and marketing of Spherotide in South Korea

19/12/2017 - 13:46

Press release 2017-12-19 Xbrane Biopharma AB ("Xbrane" or "the Company") has signed a distribution agreement with BL&H for sales and marketing of Spherotide in South Korea. Xbrane will receive mid-single digit SEK [...]

Cancer Genetics Receives New York State Approval for FDA-Approved Oncomine Dx Target Test by Thermo Fisher Scientific

19/12/2017 - 13:30

The test serves as a companion diagnostic for three targeted therapies in non-small cell lung cancer (NSCLC) Global NSCLC diagnostic market projected to reach $3.65 billion by 2024 RUTHERFORD, N.J., Dec. 19, 2017 (GLOBE [...]

BioCorRx Submits Pre-IND Package to FDA for its Naltrexone Implant, BICX102

19/12/2017 - 13:30

ANAHEIM, CA, Dec. 19, 2017 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that it has [...]

REPEAT – Cannabis Wheaton Income Corp. Announces Exclusive Data Licensing Agreement With Prominent Cannabis Testing, Analysis and Rating Company

19/12/2017 - 13:30

VANCOUVER, British Columbia, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Cannabis Wheaton Income Corp. (d/b/a Wheaton Income) (TSX.V:CBW) (“ Wheaton Income ” or the “ Company ”) is pleased to announce that it has entered into an [...]

Onconova Therapeutics Announces License and Collaborative Development Agreement with HanX Biopharmaceuticals for ON 123300, a Dual Inhibitor of CDK4/6 + ARK5

19/12/2017 - 13:30

HanX to commercialize in Greater China: Onconova retains rights in rest of the world HanX will fund studies towards Investigational New Drug (IND) applications in both the US and China Agreement includes licensing fee, [...]

Myriad Genetics to Present at the 36th Annual J.P. Morgan Healthcare Conference

19/12/2017 - 13:05

SALT LAKE CITY, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN ), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled [...]

Faron Pharmaceuticals Oy: Study update: Traumakine® Phase II/III INFORAAA trial for Multi-Organ Failure receives recommendation from IDMC

19/12/2017 - 13:01

Faron Pharmaceuticals Ltd ("Faron" or the "Company") Study update: Traumakine ® Phase II/III INFORAAA trial for Multi-Organ Failure receives recommendation from IDMC First recommendation received from the IDMC to [...]

PTS Diagnostics Announces New Portable Data Capture System for Screening Professionals

19/12/2017 - 13:00

INDIANAPOLIS, Dec. 19, 2017 (GLOBE NEWSWIRE) -- PTS Diagnostics, a U.S.–based manufacturer of point-of-care biometric testing devices, today announced that they are releasing PTS Connect TM ScreenPro, a portable data [...]

REGENXBIO Announces IND Active for Phase I/II Trial of RGX-121 to Treat Mucopolysaccharidosis Type II

19/12/2017 - 13:00

Novel, one-time, direct-to-CNS treatment for MPS II focused toward potentially preventing the progression of cognitive deficits Clinical trial expected to enroll children with MPS II Anticipate beginning trial [...]

Asterias Biotherapeutics Completes Enrollment of Entire SCiStar Study

19/12/2017 - 13:00

FREMONT, Calif., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced enrollment and dosing of the last [...]